This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Ticker(s): ALT, LLY, NVOWho's the expert?
- Retired from active practice in Sept 2021 and now teach in the clinics only
- 800-900 patients with type 1 diabetes at time of retirement and directed the clinical diabetes center at Washington University School of medicine.
- Professor of medicine, Division of Endocrinology at Washington University
- Former director of the Washington University diabetes center at Barnes-Jewish Hospital
Interview GoalDiscussing the NASH treatment landscape and the potential of Altimmune's study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
